Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review

Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review

BackgroundUpper tract urothelial carcinoma (UTUC) is a rare malignancy. The management of metastatic or unresectable UTUC is mainly based on evidence extrapolated from histologically homologous bladder cancer, including platinum-based chemotherapy and immune checkpoint inhibitor alone, whereas UTUC...

Full description

Bibliographic Details
Main Authors: Tianyuan Xu, Hanxu Guo, Jun Xie, Yanyan He, Jianping Che, Bo Peng, Bin Yang, Xudong Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
upper tract urothelial carcinoma
immunochemotherapy
TP53/MDM2
ErbB2
luminal-infiltrated
circulating tumor DNA (ctDNA)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1119343/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1119343/full

Similar Items